Aclaris Therapeutics, Inc. 8-K

What Happened
Aclaris Therapeutics, Inc. announced its financial results for the quarter and full year ended December 31, 2025 via a press release issued February 26, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8‑K filed the same day; the filing was signed by CFO Kevin Balthaser.

Key Details

• Filing date: February 26, 2026 (Form 8‑K Item 2.02: Results of Operations and Financial Condition).
• Period covered: quarter and full year ended December 31, 2025.
• Press release furnished as Exhibit 99.1; cover page provided in Inline XBRL as Exhibit 104.
• Form 8‑K signature: Kevin Balthaser, Chief Financial Officer.

Why It Matters
This 8‑K notifies investors that Aclaris has released its latest quarterly and annual financial results—information that typically includes revenue, earnings or losses, and management commentary. Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial figures and any operational highlights, and watch for subsequent detailed filings (e.g., 10‑K) or an earnings call for fuller context.